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ARTICLE
Nrf2 negatively regulates STING indicating a link
between antiviral sensing and metabolic
reprogramming
David Olagnier1, Aske M. Brandtoft 1, Camilla Gunderstofte1, Nikolaj L. Villadsen2, Christian Krapp1,
Anne L. Thielke1, Anders Laustsen1, Suraj Peri3, Anne Louise Hansen1, Lene Bonefeld1, Jacob Thyrsted1,
Victor Bruun1, Marie B. Iversen1, Lin Lin1, Virginia M. Artegoitia 4, Chenhe Su5, Long Yang5, Rongtuan Lin5,
Siddharth Balachandran3, Yonglun Luo 1,6, Mette Nyegaard 1, Bernadette Marrero7,
Raphaela Goldbach-Mansky7, Mona Motwani8, Dylan G. Ryan9, Katherine A. Fitzgerald8, Luke A. O’Neill9,
Anne K. Hollensen10, Christian K. Damgaard10, Frank v. de Paoli1, Hanne C. Bertram4, Martin R. Jakobsen 1,
Thomas B. Poulsen2 & Christian K. Holm1
The transcription factor Nrf2 is a critical regulator of inﬂammatory responses. If and how Nrf2
also affects cytosolic nucleic acid sensing is currently unknown. Here we identify Nrf2 as an
important negative regulator of STING and suggest a link between metabolic reprogramming
and antiviral cytosolic DNA sensing in human cells. Here, Nrf2 activation decreases STING
expression and responsiveness to STING agonists while increasing susceptibility to infection
with DNA viruses. Mechanistically, Nrf2 regulates STING expression by decreasing STING
mRNA stability. Repression of STING by Nrf2 occurs in metabolically reprogrammed cells
following TLR4/7 engagement, and is inducible by a cell-permeable derivative of the TCA-
cycle-derived metabolite itaconate (4-octyl-itaconate, 4-OI). Additionally, engagement of
this pathway by 4-OI or the Nrf2 inducer sulforaphane is sufﬁcient to repress STING
expression and type I IFN production in cells from patients with STING-dependent inter-
feronopathies. We propose Nrf2 inducers as a future treatment option in STING-dependent
inﬂammatory diseases.
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Nrf2 (Nuclear factor (erythroid-derived 2) -like 2) is amember of the cap´n´collar basic leucine zipper family oftranscription factors characterized structurally by the
presence of Nrf2-ECH homology domains1. At steady state, Nrf2
is kept inactive in the cytosol by its inhibitor protein Keap1
(Kelch-like ECH-associated protein 1), which targets Nrf2 for
proteasomal degradation2. In response to oxidative stress, Keap1
is inactivated and Nrf2 is released to induce the transcription of
Nrf2-responsive genes. In general, the genes under the control of
Nrf2 protect against stress-induced cell death and Nrf2 has thus
been suggested as the master regulator of tissue damage during
infection3. Furthermore, Nrf2 is also an important regulator of
the inﬂammatory response4,5 and was recently identiﬁed to
function as a transcriptional repressor of inﬂammatory genes in
murine macrophages6.
Type I IFNs (IFNα and -β) are central to immune-protection
against infection with virus. Production of IFNα/β in response to
infection is highly dependent on innate recognition of cytosolic
viral nucleic acids by cellular pathogen recognition receptors
(PRRs). These receptors include the RNA sensors RIG-I and
MDA-5, which signal through the adaptor MAVS7,8, and the
DNA sensor cGAS which signals through the adaptor STING9–12.
In both signaling pathways, binding of viral nucleic acids to their
respective sensors leads to recruitment and phosphorylation of
the kinase TBK1 (Tank Binding Kinase 1), which in turn activates
the IRF3 transcription factor by phosphorylation13–15. Whereas a
balanced production of type I IFNs is necessary for protection
against virus, excessive production hereof is a powerful driver of
pathology. This has recently been demonstrated in inﬂuenza A
virus infections16 as well as in a series of auto-inﬂammatory
disorders such as systemic lupus erythematosus17,18 and in the
more recently discovered disease STING-associated vasculopathy
with onset in infancy (SAVI)19. In the latter case, gain-of-
function mutations in STING drives a systemic and debilitating
inﬂammatory condition19. Tight regulation of type I IFNs is thus
necessary to avoid excessive immune mediated tissue damage in
infection as well as in homeostasis. If and how Nrf2 affects type I
IFN responses induced by antiviral cytosolic sensing and if the
Nrf2/Keap1 axis is a potential target for treating STING-
dependent interferonopathies is, however, not currently known.
The role of biochemistry has recently gained a newfound
foothold in innate immunology. Studies dating back from the
1970s showed that microbial products, such as LPS (lipopoly-
saccharide), negatively regulate respiration of macrophages by
inhibiting complexes in oxidative phosphorylation20,21. These
early discoveries have now formed the basis of a completely new
area of immunology referred to as immunometabolism22. Meta-
bolic reprogramming is now known to include an increase in
glycolysis and a two-point interruption of the tricarboxylic acid
(TCA) cycle23,24. Recent work has now demonstrated that an
important result of metabolic reprogramming, induced through
stimulation with LPS, is the accumulation of distinct TCA-cycle
derived metabolites—in particular succinate and itaconate25,26.
Earlier work demonstrated that succinate operates as a pro-
inﬂammatory agent and is important for the release of IL-1β25.
The anti-inﬂammatory effect of endogenous itaconate was initi-
ally described in Irg1 deﬁcient murine macrophages that lack
itaconate production27. Further, itaconate has been demonstrated
to have anti-inﬂammatory properties by inhibiting the enzymatic
activity of succinate dehydrogenase (SDH) to accumulate succi-
nate25–27. Moreover, a recent report demonstrated that a cell-
permeable derivative of itaconate (4-octyl-itaconate, 4-OI) blunts
transcription of IL-1β through activation of the transcription
factor Nrf2, which acts as a repressor of IL-1β transcription28.
Altogether, these reports contribute to a growing body of evi-
dence for a dependency on metabolic reprogramming for the
control of pro-inﬂammatory cytokine release. No reports have so
far demonstrated a link between cellular accumulation of meta-
bolites and regulation of antiviral cytosolic sensing.
In this study, we demonstrate that Nrf2 represses antiviral
cytosolic sensing by suppressing the expression of the adaptor
protein STING. Further, we show that the repression of STING
expression occurs during metabolic reprogramming following
TLR ligation and is inducible by 4-OI, the cell-permeable deri-
vative of the TCA-cycle metabolite itaconate, through activation
of Nrf2. Finally, treatment with Nrf2 inducers, including 4-OI,
sufﬁciently reduces STING-dependent release of type I IFNs from
SAVI-derived ﬁbroblasts promoting the idea that Nrf2 is a valid
target in STING-associated inﬂammatory disorders.
Results
Nrf2 represses STING mRNA and protein levels in human
cells. To test whether the transcription factor Nrf2 affects the
innate antiviral program, we used a full transcriptome analysis to
identify differentially regulated pathways and genes in human
cells silenced for Nrf2. As an experimental tool, we used the
human epithelial cell line A549 which harbors a loss-of-function
mutation in Keap1, thus rendering Nrf2 constitutively active in
these cells29. A total of 1511 genes were signiﬁcantly regulated
between control and Nrf2 silenced cells (Supplementary Fig. 1a).
A functional clustering (node analysis) using this gene list iden-
tiﬁed an intersection between Nrf2 signaling with antiviral-
associated pathways (Fig. 1a). Among the differentially expressed
genes were several genes involved in type I (α/β) interferon
response and in antiviral sensing and signaling—including
TMEM173, the gene encoding the innate adaptor molecule
STING30 (STimulator of INterferon Genes) (Fig. 1b, c and Sup-
plementary Fig. 1b–c). STING is central to the release of type I
IFNs in response to cytosolic DNA and signals downstream of the
cytosolic DNA sensor cGAS9,31,32—suggesting that Nrf2 is a
negative regulator of STING-dependent type I IFN responses. In
contrast, transcripts from known Nrf2-inducible genes such as
Nrf2 itself (NFE2L2), HMOX-133, and NQO134 were all decreased
by siRNA-mediated silencing of Nrf2 (Fig. 1b and Supplementary
Fig. 1b). We were able to validate the regulatory role of Nrf2 on
TMEM173 mRNA levels by multiple qPCR experiments in A549
and also in human keratinocyte HaCat cells, which were instead
silenced for the Nrf2 repressor Keap1 (Fig. 1d–g). The regulation
of TMEM173 mRNA was sufﬁcient to affect STING protein levels
as A549 cells lacking Nrf2, following CRISPR/Cas9 gene editing
or treatment with two different Nrf2 targeting siRNAs, displayed
markedly increased levels of STING protein while other major
signaling molecules such as cGAS, IFI16, RIG-I, MDA5, MyD88,
and TBK1 were unaffected (Fig. 1h and Supplementary Fig. 2a).
In line, both CRISPR/Cas9 silencing of Nrf2 in A549 and siRNA-
mediated Keap1 silencing in HaCat cells affected STING
expression—again without affecting other important signaling
molecules (Supplementary Fig. 2a and Fig. 1i). Further, treatment
of A549 cells with the Nrf2 inhibitor ML38535 led to decreased
expression of HO-1 and increased expression of STING (Sup-
plementary Fig. 2c). The effect of the Nrf2/Keap1 pathway on
STING protein expression was quantiﬁed and statistically con-
ﬁrmed in multiple western blot experiments (Fig. 1j, k). Notably,
the repression of STING by Nrf2 was restricted to human cells as
the lack of Nrf2 in murine bone-marrow derived macrophages
from Nrf2–/– mice or Nrf2/Keap1 CRISPRed RAW 264.7 mac-
rophages did not interfere with STING expression (Supplemen-
tary Fig. 3). Importantly, silencing of Nrf2 in primary human
monocyte-derived macrophages (hMDMs) also led to increased
STING mRNA and protein levels demonstrating that the reg-
ulatory effect of the Nrf2/Keap1 axis on STING was not limited to
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cell lines but also occurred in primary human cells (Fig. 1l–n). To
approach the role of Nrf2 in a complimentary manner, we
demonstrated that treatment of HaCat cells and cells of the
human monocytic lineage THP1 with the chemical Nrf2 activator
sulforaphane (SFN) (Supplementary Fig. 4) led to decreased
STING mRNA and protein levels (Fig. 1o, p). Further, using
HEK293 cells we investigated the effect of STING expression
when Nrf2 and STING were co-expressed. Here, co-expression of
Nrf2 greatly reduced expression of STING (Supplementary
Fig. 5a). By contrast, we were unable to affect STING expression
by silencing of the autophagy regulatory proteins ULK136 (Unc-
51 like autophagy activating kinase 1), ATG7 (Autophagy-related
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Fig. 1 Nrf2 suppresses STING expression. A549 cells were transfected with control or Nrf2 siRNA for 48 h. Samples were analysed by RNAseq and
differentially expressed pathways and genes that satisﬁed p-value <0.001 and fold change cutoff >1 or <−1 were selected. The data are from one
experiment performed in triplicate. a Heat map of differentially regulated genes and a listing of representative gene ontologies and KEGG pathways
associated with these genes. b Cloud analysis of differentially expressed genes. c Representation of RNA-reads for from RNAseq. Graph displays boxplots
with boxes indicating mean, s.e.m. as well as min and max values. d–g Cells were transfected with control, Nrf2 or Keap1 siRNA for 48 h or 72 h,
respectively. TMEM173 and HMOX-1 mRNA expression levels were monitored by qPCR. Each two connected dots represent data from one biological
experiment with paired samples. h, i Antiviral sensor, adaptor or accessory molecules were examined by immunoblotting. Data are representative of two
independent experiments. j Correlation between Keap1 and STING protein levels in HaCat cells and Nrf2 and STING protein levels in A549 cells using
Image J quantiﬁcation of western blot intensities. Correlations were calculated using a Spearman's test. Each dot represents a biological sample. k
Quantiﬁcation of STING staining intensities in multiple western blots using Image J. Colorations indicate sample pairing. Graphs display mean and s.e.m. l–
n TMEM173 and NRF2mRNA expression levels by qPCR (l,m) or western blotting (n) in human monocyte-derived macrophages treated with control siRNA
or Nrf2 siRNA. Data represent means ± s.e.m. of experiments performed on two donors. o–r PMA-differentiated THP1 cells (o) or HaCat cells (q and r)
were stimulated with L-sulforasphane (SFN) (20 μM) for 72 h. TMEM173 mRNA and STING protein levels were determined by qPCR and immunoblotting,
respectively. Data are from one representative experiment which has been repeated twice. Two-tailed Student’s t-test was used to determine statistical
signiﬁcance
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protein 7)37, or SQSTM1(p62)38 in A549 cells (Supplementary
Fig. 6). Further, co-silencing of these autophagy proteins did not
affect the suppression of STING expression in HaCat cells by
removal of Keap1, thus demonstrating that suppression of STING
is autophagy-independent in this context (Supplementary Fig. 6).
Impairment of STING expression by Nrf2 also seemed inde-
pendent of type I IFN and of increased reactive oxygen species
(ROS) accumulation as neither silencing of IFNAR nor treatment
with the ROS scavenger L-NAC affected STING suppression.
Furthermore, no induction of IFNβ1 mRNA was observed by
Nrf2 silencing (Supplementary Fig. 7, 8). Additionally, individual
silencing of a cross-section of Nrf2 differentially regulated genes
uncovered from our RNAseq analysis did not modulate STING
expression in A549 cells (Supplementary Fig. 8). No physical
interaction between Nrf2 and STING protein was detected as we
were unable to co-precipitate Nrf2 with STING in immunopre-
cipitation experiments using HEK293 where both STING and
Nrf2 were overexpressed (Supplementary Fig. 9). Finally, treat-
ment of A549 with the proteasomal inhibitor MG-132 did not
signiﬁcantly elevate STING protein levels while the protein levels
of MDM2 and cyclin B, which are known to be sensitive to MG-
132, were highly affected by the treatment (Supplementary Fig. 9).
Nrf2 regulates STING mRNA stability. A recent report
demonstrated that Nrf2 can bind to a DNA region in the
proximity of the IL-1β promoter in murine macrophages6. From
this position, Nrf2 decreases the recruitment of the RNA poly-
merase II (Pol II) to the IL-1β gene and hereby negatively reg-
ulates IL-1β expression6. We hypothesized that Nrf2 regulates
STING expression in a similar manner in human cells and thus
performed a ChIP-seq analysis using a Nrf2 speciﬁc antibody and
A549 cells in which Nrf2 is constitutively active. Here we found
that although Nrf2 peaks were readily detectable in the proximity
of known Nrf2 regulated genes such as NQO1, no detectable Nrf2
peak was present in proximity to TMEM173 locus (Fig. 2a, b). To
decrease the risk of having erroneously disregarded or overlooked
a Nrf2 peak we also performed the peak calling with a more
relaxed cutoff (p-value 1e−3). With these looser settings, we
identiﬁed a small Nrf2 peak located ~25 kb from TMEM173
(Supplementary Fig. 10a). However, deletion of this genomic
region in A549 cells with CrisprCas9 technology led to a slight
decrease rather than an increase in STING expression (Supple-
mentary Fig. 10b) thereby supporting the ﬁnding that Nrf2 does
not regulate STING through a direct genomic interaction in a
region in close proximity to TMEM173. As the effect of Nrf2 on
TMEM173 transcription might be indirect we then performed
another ChIP-seq, this time using an RNA Pol II-speciﬁc anti-
body and A549 cells treated with either control or Nrf2 targeted
siRNA. Much to our surprise, presence of RNA Pol II on
TMEM173 was below the level of detection in both of the siRNA-
treated groups. By sharp contrast, recruitment of the RNA Pol II
to the Nrf2-regulated gene TXNRD1 was detectable in both
groups and was highly impaired by the silencing of Nrf2 (Fig. 2c,
d). The relatively limited presence of RNA Pol II in the
TMEM173 gene suggested a weak transcriptional control of
TMEM173 in A549 cells and evoked the possibility of a post-
transcriptional regulation of TMEM173 gene by Nrf2. This was
also supported by the relatively low number of reads for
TMEM173 detected by RNAseq (Fig. 1c). As we had already
determined that Nrf2 affected TMEM173 mRNA levels, we
hypothesized that Nrf2 regulates TMEM173 mRNA levels by
affecting mRNA stability. To test this hypothesis, we used A549
cells treated with either control or Nrf2 targeted siRNA and
further treated with actinomycin D (ActD). ActD binds to DNA
at the transcription initiation complex and prevents elongation of
RNA chain by RNA polymerase, thus inhibiting de novo tran-
scription. We then determined how TMEM173 and MB21D1
(cGAS) mRNA levels changed over time after transcription was
blocked. Interestingly, whereas MB21D1 mRNA levels quickly
decreased, TMEM173 mRNA levels were stable within the ﬁrst 4
h of ActD exposure and there was no observable effect of
Nrf2 silencing (Fig. 2e, f). These data demonstrated that
TMEM173 mRNA is highly stable and that STING and cGAS
expression is likely to be regulated in different manners. We then
expanded on these experiments to include time points beyond 4
h. Here we were able to observe a signiﬁcant decrease in
TMEM173 mRNA levels in the cells treated with control siRNA
exposed to ActD from 6–18 h. Interestingly, in the Nrf2 siRNA-
treated cells TMEM173 mRNA levels remained stable and hereby
demonstrated that Nrf2 affects STING mRNA stability and sug-
gests that this is the mechanism by which Nrf2 controls STING
expression (Fig. 2g). Notably, the stability ofMB21D1 mRNA was
unaffected by Nrf2 silencing at these time points and the stability
of Nrf2 mRNA seemed to be even decreased when Nrf2 was
silenced (Fig. 2h, i). The same ﬁndings were observed in HaCat
keratinocytes that were silenced for Keap1 (Fig. 2j). On a pro-
longed period of ActD, stability of TMEM173 mRNA was low-
ered by the lack of Keap1 (Fig. 2k). Importantly, the stability of
cGAS mRNA was unaffected following Keap1 silencing (Fig. 2l).
As mRNA stability and efﬁciency of translation is often inter-
dependent, we performed a polysome proﬁling of TMEM173
mRNA in HaCat cells treated with either control or
Keap1 siRNA. Here, the association of STING mRNA with
polysomes was unaltered between the two treatment groups and
thus we suggest that changes in translation efﬁciency is not a
strong regulator of STING expression by the Nrf2/Keap1 pathway
(Supplementary Fig. 11). Together these data demonstrate that
Nrf2 regulates STING mRNA stability and suggest that this
process is a post-transcriptional regulatory mechanism by which
Nrf2 can control STING expression in human cells.
Nrf2 regulates STING-dependent antiviral immune responses.
As Nrf2 repressed STING expression, we further asked whether
impairment of STING expression was sufﬁcient to affect its
antiviral functionality and capacity to respond to cytosolic DNA
and cGAMP. Indeed, silencing of Nrf2 in A549 and of Keap1 in
HaCat cells affected downstream STING signaling events
including phosphorylation of TBK1 and IRF313 in response to the
STING agonist cGAMP (Fig. 3a, b). Additionally, expression of
IFNβ1 and subsequent induction of IFN-stimulated genes were
greatly affected by silencing of Nrf2 either by siRNA or by
CRISPR/Cas9 editing (Fig. 3c, d). This was also the case when
Nrf2 was activated in THP1 cells by pre-treatment with SFN prior
to engagement with cGAMP (Fig. 3e–g). As STING is critical for
innate protection to infection with DNA viruses in both of these
cell types (A549 and HaCat) (Supplementary Fig. 12), we tested
the effect of removing Nrf2 on the susceptibility to herpes simplex
virus (HSV) infection. Here, silencing of Nrf2 in A549 cells
decreased infectivity with a GFP-expressing HSV-1 strain (KOS)
(Fig. 3h) and suppressed the release of progeny virus when
infected with two different HSV-2 strains (MS and 333) (Fig. 3i,
j). In further support of Nrf2 regulating a STING-dependent
antiviral response we observed that in HEK293 cells stably
expressing STING the expression of Nrf2 reduced the IFN-
response to known STING agonists, including HSV-1 (Supple-
mentary Fig. 5b–d).
Nrf2 suppresses STING during metabolic reprogramming.
Metabolic reprogramming in immune cells is inducible in mac-
rophages or dendritic cells by stimulation with LPS25,39. LPS is
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long known to activate Nrf240. Thus, we hypothesized that Nrf2
could also be a repressor of STING in a context of metabolic
reprogramming. As metabolic reprogramming is triggered by
toll-like receptors (TLRs) we chose a human pDC cell line
(PMDC05), which is known to be highly sensitive to stimulation
through these receptors41,42. As expected, we were able to
demonstrate that treatment of PMDC05 cells with the TLR4
agonist LPS or the TLR7 agonist gardiquimod led to increased
release of lactate, increased glucose consumption, enhanced
accumulation of itaconate, as well as increased expression of
HIF1α—the hallmarks of metabolic reprograming in innate
immune cells (Fig. 4a–c). Notably, in this context we were able to
observe a time-dependent repression of STING expression in a
manner very similar to that observed with a genetic or chemical
activation of Nrf2 (Fig. 4e, f). By contrast, expression of other
innate signaling molecules such as RIG-I, MAVS, and MDA-5
was not reduced but rather increased in response to TLR ligation
(Fig. 4e). Notably, the expression of the Nrf2 inducible enzyme
heme-oxygenase-1 (HO-1) was enhanced following TLR4 or
TLR7 agonist treatment supporting a possible link between Nrf2
activation and STING suppression during LPS-induced metabolic
reprogramming. This link was conﬁrmed as treatment of
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Fig. 2 Nrf2 regulates STING mRNA stability. a, b A549 cells were lysed and subjected to ChIP-seq using a Nrf2 speciﬁc antibody. Graphs display fragment
pileup per 1 million reads at the genomic loci proximal to TMEM173 (a) and NQO-1 (b). c, d A549 cells were treated with either control (ctrl) or Nrf2
targeted siRNA for 48 h. Cells were then lysed and subjected to ChIP-seq analysis using a Pol II-speciﬁc antibody. Graphs display fragment pileup per 1
million reads at the genomic loci surrounding TMEM173 (c) and TXNRD1 (d). e–i A549 cells were treated with ctrl or Nrf2 siRNA for 48 h. Knockdown
efﬁciency of Nrf2 was determined by qPCR (e). f–i Cells were then treated with Actinomycin D (10 µg/mL) as indicated and gene expression was
determined by qPCR. The graph in (f) is one representative of two independent experiments. The graphs in (g) and h contains merged data from two
independent experiments with n= 5 at the 8 h timepoint and n > 2 for remaining time points. Data displayed in (i) represent one experiment with n= 3. (*)
indicates statistical signiﬁcance using Student’s t-test with p < 0.05. j–l HaCat cells were treated with ctrl or Keap1 siRNA for 72 h. Knockdown efﬁciency of
Keap1 was determined by qPCR (j). k, l Cells were then treated with Actinomycin D (5 µg/mL) as indicated and gene expression was determined by qPCR.
Data displayed in (k) and l represent one experiment with n= 3. (*) indicates statistical signiﬁcance using Student’s t-test with p < 0.05
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PMDC05 cells with the Nrf2 inhibitor ML385 largely abolished
the effect of LPS and gardiquimod on STING expression (Fig. 4g).
The suppression of STING expression by TLR ligation was suf-
ﬁcient to signiﬁcantly inhibit its functionality as pre-treatment
with LPS abolished the release of type I IFNs in response to the
STING agonist cGAMP (Fig. 4h). A recent report demonstrated
the electrophilic nature of the citrate-derived metabolite itaconate
and its ability to activate the Nrf2 pathway through direct binding
of Keap143. At the same time, the O’Neill’s group demonstrated
that also the itaconate derivative 4-OI can bind Keap1 to promote
Nrf2 activity28. We therefore hypothesized that 4-OI might also
be able to affect STING expression through activation of Nrf2
(Fig. 4i). We were able to conﬁrm 4-OI as a potent Nrf2 activator
as we observed a dose-dependent increase in a luciferase-based
Nrf2-promoter activity assay in response to 4-OI (Fig. 4j). Then, a
strong reduction in TMEM173 mRNA levels was observed fol-
lowing stimulation with 4-OI in cells of the human monocytic cell
line THP1, thus supporting the existence of an itaconate/Nrf2
link in the regulation of STING. By contrast, 4-OI did not affect
cGAS (MB21D1) expression levels and expression of the Nrf2-
inducible gene HMOX-1 was highly increased (Fig. 4k). Further,
treatment with 4-OI was sufﬁcient to greatly impair STING
protein expression and STING-dependent signaling in response
to cGAMP (Fig. 4l). The strength of this suppression was sufﬁ-
cient to also inhibit release of type I IFNs as well as downstream
STAT1 signaling and subsequent induction of ISGs (Fig. 4m, n).
The effect of 4-OI treatment depended on Nrf2 as silencing
hereof by siRNA decreased the suppression of STING in HaCat
cells (Fig. 4o and Supplementary Fig. 14) and in A549 cells
(Fig. 4p). We also performed siRNA-mediated silencing of Nrf2
in primary hMDMs. Here, silencing of Nrf2 largely abolished the
effect of 4-OI on STING expression in cells from two different
healthy human donors (Fig. 4q–s and Supplementary Fig. 13).
These data demonstrate that STING expression is repressed by
LPS and by 4-OI through activation of Nrf2 and hereby suggest
si ctrl
a
si Nrf2
Keep1
HO-1
STING
pIRF3
IRF3
VCL
si ctrl
b
si Keap1
– + – +cGAMP
– + – +cGAMP
pSTING
STING
pTBK1
TBK1
Nrf2
HO-1
VCL
35
***
**
***
*
*
30
25
IF
N
B1
 m
R
N
A 
(N
R)
20
15
10
5
0
Nt NtDNA
si ctrl si Nrf2
c
No guides Nrf2 guides
si ctrl si Nrf2d
Nrf2
HO-1
STING
pSTAT
STAT1
IFIT1
ISG15
VCL
– + – +cGAMP
DNA Nt NtDNA DNA
***
Nt SFN cGAMP cGAMP
+SFN
0.08
0.06
0.04
0.02
0.00
IF
N
B1
 
m
R
N
A
***
Nt SFN cGAMP cGAMP
+SFN
g 0.4
0.3
0.2
0.1
0.0
CX
CL
10
 
m
R
N
A
si Nrf2
Gating strategy si ctrl
GFP+
32,2
GFP+
14,5
GFP
Si
de
 s
ca
tte
r
105
105
104
104
103
103
–103
–103
0
Si
de
 s
ca
tte
r
105
104
103
–103
0
0
GFP
105104103–103 0
Cell gate
SSC single cell gate
Single cells (FCS)
94.6
FCS single cell gate
Single cells (SSC)
94.6
Cells
97.3
si Nrf2si ctrl
10
Vi
ru
s 
tit
er
s 
(*1
03  
pf
u/
m
L)
j
si Nrf2si ctrl
5
4
3
2
1
0Vi
ru
s 
tit
er
s 
(*1
03  
pf
u/
m
L)
8
6
4
2
0
SF
N 
20
STING
STING
pTBK1
TBK1
pIRF3
(pIRF3)2
pIRF3
IRF3
(IRF3)2
IRF3
Nrf2
HO-1
NqO1
VCL
(STING)2
SF
N 
10
N
tSF
N 
20
SF
N 
10
N
t
f h ie cGAMP
Fig. 3 Nrf2 impairs antiviral innate immunity and increases susceptibility to DNA virus infection. a, b A549 cells (a) or HaCat cells (b) were transfected
with Nrf2 or Keap1 siRNA for 48 h or 72 h, respectively, and were subsequently challenged with cGAMP for 3 h (4 μg mL−1). Whole-cell extracts were
analysed for STING signaling events by immunoblotting. Blots in (a) and b are representative of >6 independent experiments. c A549 cells silenced for
Nrf2 using siRNA or lacking Nrf2 after CRISPR/Cas9 editing were stimulated with dsDNA (4 μg mL−1). IFNB1 mRNA levels were determined by qPCR. Data
are the means ± s.e.m. of an experiment performed in triplicate. d A549 cells were transfected with control or Nrf2 siRNA for 48 h and were subsequently
challenged with cGAMP for 24 h (4 μgmL−1). Whole-cell extracts were analysed for ISG expression by immunoblotting. Blot is representative of more than
four independent experiments. e–g PMA-differentiated THP1 cells were pre-treated with increasing doses of L-sulforaphane (SFN) for 72 h and
subsequently stimulated with cGAMP (4 μg mL−1) for 3 h (f) or 6 h (f, g). Whole-cell extracts were analysed for antiviral signaling events by
immunoblotting (e) and IFNβ1 and CXCL10 gene expression by qPCR (f, g). Blot in e is representative of three independent experiments. Data in (f) and g
are the means ± s.e.m. of an experiment performed in triplicate. h–j A549 cells were transfected with control or Nrf2 siRNA for 48 h and were subsequently
infected with HSV-1-GFP (KOS strain), or HSV-2 (MS and 333 strains) at an MOI of 0.01 for 24 h. Viral infectivity was determined by ﬂow cytometry (h)
and viral replication by plaque assay (i, j). h Graphs display gating strategy (left) and GFP intensity by ﬂow cytometry (right). i, j Graphs display mean and
s.e.m. of plaques two independent experiments. Data presented in (h–j) are representative of two independent experiments. Unpaired two-tailed Student’s
t-test was used to determine signiﬁcance of the difference between the control and each experimental condition
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-05861-7
6 NATURE COMMUNICATIONS |  (2018) 9:3506 | DOI: 10.1038/s41467-018-05861-7 | www.nature.com/naturecommunications
6a b c d e
9.5
Cell medium Cell pellet
HIF1α
STING
HO-1
RIG-I
MDA-5
MAVS
pSTAT1
VCL
IFIT1
VCL
15 6
5
4
Nt
LP
S 24 hours 48 hours 72 hoursNt LP
S
10
5
9.0
8.5
8.0
5
La
ct
at
e 
(m
M
)
Ita
co
na
te
 (
m
M
)
N
t
N
t
N
t
LP
S
LP
S
C
pG
pI
C
LP
S
G
ar
di
G
ar
di
G
ar
di
cG
A
M
P
N
t
LP
S
C
pG
pI
C
G
ar
di
cG
A
M
P
N
t
LP
S
C
pG
pI
C
G
ar
di
cG
A
M
P
Ita
co
na
te
 (
re
la
tiv
e 
am
ou
nt
s)
G
lucose (m
M
)
4
3
Nt
LP
S
Ga
r Nt
LP
S
Ga
r
f g h i
Repression of
STING
expression
ML385 – + – + – +
Nt LPS
TM
EM
17
3 
m
R
N
A
 (
N
R
)
Ty
pe
 I 
IF
N
 (
U
/m
L)
0.04
0.03
0.02
0.01
0.00
Nt
Ga
rd
i
Gardi
HO-1
600
400
200
0
STING
VCL
Cp
G
pI
C
cG
AM
P
Nt LPS
4-OI
octyl
octyl
O
O
O
O
S
SH
Keap1
Keap1
+
Nrf2
Nrf2
OH
OH
O
O
LP
S
**
*
*
**
cGAMP
Gar Nt LPS Gar
j k
l
TMEM173
HMOX-1
MB21D1 (cGAS)
A
R
E
-lu
c 
ac
tiv
ity
m
R
N
A
 le
ve
ls
 (
N
R
)
16
8
4
2
1
0.5
0.25
0.125
0.062
7.5
5.0
2.5
0.0
Nt SFN
SFN4-OI 4-OI
4-OI
Nt Nt
pSTING
STING
(STING)
2
(STING)
pTBK1
TBK1
pIRF3
(pIRF3)
2
pIRF3
IRF3
IRF3
Nrf2
HO-1
NqO1
VCL
(IRF3)
2
q r s
TM
EM
17
3 
m
R
N
A
 (
N
R
)
TM
EM
17
3 
m
R
N
A
 (
N
R
)4
2
2
0
0.5
0.25
0.16
0.12
0
0.5
0.25
si– ctrl Nrf2 Nrf2
4-OI 4-OI
4-OI
ctrl si– ctrl Nrf2 Nrf2ctrl
hMDM
Donor 1
Donor 1
hMDMhMDMDonor 2
Donor 2
HO-1
NqO1
SQSTM1
STING
VCL
– + +– – + +–
si ctrl si ctrlsi Nrf2 si Nrf2
***
***
***
***
***
m
n
Ty
pe
 I 
IF
N
 (
U
/m
L)
1000
750
500
250
0
Nt
Nt 4-OI Nt 4-OI
cGAMP
STING
pSTAT1
STAT1
IFIT1
ISG15
HO-1
VCL
o
p
4-OI
HaCat
A549
4-OI
Nrf2
HO-1
VCL
STING
STING
(sh. exp)
(lo exp)
– + +–
– + +–
si ctrl
si ctrl
si Nrf2
si Nrf2
Nrf2
HO-1
STING
VCL
***
4-OI Nt
cGAMP
4-OI
Fig. 4 Nrf2 is a negative regulator of STING during metabolic reprogramming. a Lactate and glucose were measured in supernatants from PMDC05 cells
stimulated with LPS (1 μg mL−1) or gardiquimod (4 µg ml−1) for 24 h. Data are the means and s.e.m. from one of two independent experiments performed
in septuplicates. b, c Itaconate was measured in the cell medium and in the cell pellets of LPS-stimulated PMDC05 by LC/MS. Data are the means and s.e.
m. from one of two independent. d PMDC05 stimulated with LPS (200 ngmL−1) or gardiquimod (400 ngml−1) for 24 h were lysed and analysed for HIF1α,
IFIT1, and Vinculin (VCL) as loading control. e PMDC05 cells were stimulated with gardiquimod (4 μg mL−1), LPS (1 μg mL−1), CpG (4 μg mL−1), cGAMP
(4 μg mL−1), or Poly (I:C) (4 μgmL−1) for 24, 48, or 72 h. Whole-cell extracts were analysed by immunoblotting. f TMEM173mRNA was assessed by qPCR
in PMDC05 stimulated with indicated agonists for 48 h. Data are the means ± s.e.m. of one experiment performed in triplicate. g PMDC05 cells were pre-
treated with the Nrf2 inhibitor ML385 (20 µM) before stimulation with LPS (1 μg mL−1) or gardiquimod (4 μg mL−1) for 72 h. Cells were then lysed and
lysates were analysed by western blotting. h PMDC05 cells were pre-stimulated with gardiquimod (4 μg mL−1) or LPS (1 μg mL−1) for 72 h before challenge
with cGAMP (4 μg mL−1) for 24 h. Type I IFN release was assessed using a HEK-Blue assay. Data are the means ± s.e.m. of one representative experiment
performed in triplicate. i Graphical display of how 4-OI might possibly activate Nrf2. j HEK293T cells were treated with increasing doses of 4-OI (30–250
μM) for 18 h. ARE-promoter activity was assessed by luciferase assay. Data are means ± s.e.m. of two independent experiments in triplicate. k THP1 cells
were treated with SFN (20 μM) or 4-OI (125 μM) for 48 h and mRNA levels were determined by qPCR. l THP1 cells were pre-treated with increasing does
of 4-OI (62.5–125 μM) for 72 h and challenged with cGAMP (4 μg mL−1). Whole-cell lysates were then blotted as indicated. Data are from one
representative experiment that has been repeated twice. m–n THP1 cells were pre-treated with 4-OI (125 μM) for 72 h before challenge of 24 h with
cGAMP (4 μg mL−1). Supernatants were assessed for type I IFN by HEK-Blue cell assay (m) and whole-cell lysates by immunoblotting (n). o, p HaCat and
A549 cells were treated with Nrf2 siRNA for 72 h and for 48 h, respectively, before treatment with 4-OI (125 μM) for 48 h. Whole-cell lysates were used
for immunoblotting. q–s mRNA levels (q, r) and protein levels (s) were assessed by qPCR and immunoblotting in hMDMs silenced for Nrf2 by siRNA. Data
are from two donors. Unpaired two-tailed Student’s t-test was used to determine signiﬁcance
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-05861-7 ARTICLE
NATURE COMMUNICATIONS |  (2018) 9:3506 | DOI: 10.1038/s41467-018-05861-7 | www.nature.com/naturecommunications 7
that metabolic reprogramming can control cytosolic antiviral
DNA sensing.
4-OI and SFN repress STING and IFN in SAVI ﬁbroblasts. In
addition to its protective function during infection, STING can
also be a strong inducer of immunopathology. This has recently
been demonstrated in the so-called SAVI patients19 who harbor
gain-of-function point mutations in the exon 5 of STING gene
(V174L, N152S, or V155M)19. Such STING variants are able to
secrete type I IFN spontaneously and activate an IFNβ Luciferase
reporter construct without exogenous addition of STING sti-
muli19. First, we evaluated whether induction of Nrf2 using SFN
or 4-OI could reduce STING mRNA levels in HEK293T cells
transiently expressing WT-STING or SAVI-STINGs (V174L,
N152S, or V155M). Interestingly, treatment of the STING
expressing cells with SFN or 4-OI reduced by more than twofold
TMEM173 mRNA levels (Fig. 5a, b). We then examined whether
the Nrf2 inducers could also reduce the activity of the different
SAVI-STINGs. Transient expression of the SAVI-STINGs resul-
ted in high activation of the ISRE promoter, phosphorylation of
STAT1, and induction of ISG56 expression (Fig. 5c–f). In sharp
contrast, treatment of the cells with the two different Nrf2
inducers led to a reduction in ISRE promoter activity, an inca-
pacity to phosphorylate STAT1 and to upregulate ISG56 which
corroborated with an impaired expression of STING (Fig. 5c–f).
To further examine whether activation of Nrf2 could possibly
be a future approach for treating STING-dependent inﬂamma-
tory diseases, we used immortalized ﬁbroblasts from three
patients who harbor gain-of-function mutations in STING and
who are diagnosed with SAVI19. Although harboring a gain-of-
function mutation in STING, ﬁbroblasts from SAVI patients do
not spontaneously release type I IFN or upregulate ISGs but are
highly responsive to STING ligands19. Here we observed that
treatment with SFN reduced STING expression, STING signaling
and release of type I IFN as well as subsequent induction of ISGs
in response to stimulation with cGAMP (Fig. 5g–j). Exploiting
metabolic reprogramming for treatment of patients with
inﬂammatory diseases, including those that depend on STING,
could be an attractive therapeutic strategy. We therefore tested if
4-OI treatment of immortalized ﬁbroblasts from patients
diagnosed with SAVI patients was sufﬁcient to affect STING
expression and responsiveness to STING agonists in these cells.
Here we found that 4-OI inhibited STING expression and
subsequently STING signaling in response to cGAMP (Fig. 5k–n).
Discussion
With this report, we demonstrate that Nrf2 can regulate cytosolic
antiviral sensing of DNA and the subsequent release of antiviral
type I IFNs by repressing STING expression. This regulation
occurred during LPS-induced metabolic reprogramming and
hereby suggests that metabolic reprogramming is linked to reg-
ulation of antiviral cytosolic DNA sensing. This negative feedback
loop might be beneﬁcial to the host since excessive release of type
I IFNs is associated with increased pathology in both acute and
chronic infection16,44. Considering the delay in repression of
STING by Nrf2, inhibition of type I IFN by 4-OI might be par-
ticularly relevant for reducing prolonged and pathogenic release
of type I IFNs in chronic infections. The delay in STING protein
degradation was most likely caused by the fact that Nrf2 regulated
STING post-transcriptionally. Thus, STING expression levels
slowly decreased as STING was gradually degraded through
natural cellular protein turn-over processes—while at the same
time replenishment by de novo translation was prevented
through the effect of Nrf2 on STING mRNA. The inability of
ULK1 depletion to rescue Nrf2-mediated STING repression
shows that Nrf2-mediated repression of STING expression is
truly distinct from STING-activation-induced degradation, where
STING-activation leads to a rapid degradation of STING protein
in an ULK1-dependent manner36. Autophagy is intricately linked
to Nrf2 as Nrf2 regulates the expression of several autophagy
proteins including p62/SQSTM1that has been recently involved
in the degradation of STING protein45–47. However, silencing of
the autophagy regulatory proteins ULK1, ATG7, or SQSTM1in
A549 and HaCat human cells either had no or a limited effect on
Nrf2-mediated STING repression, thus distinguishing Nrf2-
mediated repression of STING from autophagy-driven degrada-
tion of STING.
Reduction of STING expression by Nrf2 is also mechanistically
distinct from how Nrf2 reduces the release of the pro-
inﬂammatory cytokines IL-1β and IL-6. In those cases, Nrf2
bound in the proximity of the respective promoter regions and
reduced the recruitment of RNA polymerase II to the genes
encoding IL-1β and IL-66. Here, we report that TMEM173
mRNA is quite stable compared to other immune-related genes
likeMB21D1 and weakly rely on RNA Polymerase II regulation in
human A549 cells. Interestingly, we demonstrate that Nrf2
regulated STING levels by controlling TMEM173 stability. The
ability of the Nrf2 inhibitor ML385, which works by blocking
Nrf2-DNA binding35, to abrogate Nrf2-mediated suppression of
STING suggests that the effect of Nrf2 on STING is not direct but
is likely to work through a Nrf2-induced mediator.
Interestingly, although type I IFN responses might be affected
by Nrf2 in mice, the effect of Nrf2 on STING expression seemed
to be restricted to human cells as no alteration of STING was
observed in Nrf2/Keap1 knockout murine cells. Secondary
structure of the TMEM173 gene or STING mRNA, species-
speciﬁc orthologue proteins involved in the regulation of STING
mRNA or predominance of a speciﬁc biochemical degradation
pathway like autophagy in murine vs human cells, are all possible
elements that will have to be taken into consideration in a future
exploration of the difference observed in the regulation of STING
in human vs murine cells.
Finally, our demonstration that treatment with a cell-
permeable derivative of itaconate was sufﬁcient to reduce
STING-dependent release of type I IFNs from SAVI-derived
ﬁbroblasts promotes the idea that Nrf2 is a valid target in STING-
associated inﬂammatory disorders. Adopting STING-dependent
interferonopathies as diseases that could be treated like metabolic
diseases could have far reaching consequences and might possibly
lead to novel therapeutic strategies for these hard to treat diseases.
In conclusion, we have identiﬁed a link between metabolic
reprogramming and control of cytosolic antiviral sensing. This
link depends on the transcription factor Nrf2, which represses
STING expression through destabilization of STING mRNA. Our
ﬁndings add important knowledge to how release of type I IFNs is
mechanistically regulated.
Methods
Cell lines and culture conditions. Human lung adenocarcinoma epithelial A549
cells (Sigma-Aldrich), immortalized human HaCat keratinocytes (Thermo Fisher
Scientiﬁc) and human embryonic kidney HEK293T cells (Sigma-Aldrich) were
kindly provided by Søren R. Paludan (Aarhus University, Denmark) and cultured
in DMEM (Lonza) supplemented with 10% heat inactivated fetal calf serum,
200 IUmL−1 penicillin, 100 μg mL−1 streptomycin, and 600 μg mL−1 glutamine
(hereafter termed DMEM complete). HEK-Blue IFN α/β cells (Invivogen) were
cultured in DMEM supplemented with 10% heat inactivated fetal calf serum,
200 IUmL−1 penicillin, 100 μg mL−1 streptomycin, 600 μg mL−1 glutamine,
100 μg mL−1 normocin (Invivogen), 30 μg mL−1 blasticidin (Invivogen) and
100 μg mL−1 zeocin (Invivogen). HEK293 cells stably expressing STING was a kind
gift from Long Yang (McGill University). Human acute monocytic leukemia cell
line (THP1) was obtained from Martin R. Jakobsen (Aarhus University, Denmark)
and cultured in RPMI 1640 (Lonza) supplemented with 10% heat inactivated fetal
calf serum, 200 IUmL−1 penicillin, 100 μg mL−1 streptomycin, and 600 μg mL−1
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glutamine (hereafter termed RPMI complete). To differentiate THP1 cells into
adherent macrophages, cells were stimulated with 100 nM phorbol 12-myristate
13-acetate (PMA, Sigma-Aldrich) for 24 h in RPMI complete before medium was
refreshed and cells allowed to further differentiate for an additional day of culture.
The leukemic plasmacytoid dendritic cell line PMDC05 was obtained from Martin
R. Jakobsen (Aarhus University, Denmark) and cultured in RPMI (Lonza) sup-
plemented with 10% heat inactivated fetal calf serum, 200 IUmL−1 penicillin,
100 μg mL−1 streptomycin, and 600 μg mL−1 glutamine. Fibroblasts isolated from
three different SAVI patients and bearing the same STING mutation were kindly
provided by Raphaela Goldbach-Mansky (NIH, Bethesda, USA) and cultured
in DMEM (Lonza) supplemented with 10% heat inactivated fetal calf serum,
200 IUmL−1 penicillin, 100 μg mL−1 streptomycin, and 600 μg mL−1 glutamine.
All cell lines were regularly tested for mycoplasma contamination by sequencing
from GATC Biotech (Germany).
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itaconate (4-OI) (200 μM). TMEM173 mRNA levels were assessed by qPCR. Data are the means ± s.e.m. of one experiment performed in quadruplicate. c,
d HEK293T were transiently transfected with human WT and SAVI-STING plasmids (V174L, N152S, or V155M) (500 ng/mL), together with an ISRE-
Luciferase reporter. Cells were treated 1 h prior transfection of the plasmids with SFN (10 μM) or 4-octyl-itaconate (4-OI) (200 μM). Luciferase activity
was assessed 24 h after transfection. Data are the means ± s.e.m. of one experiment performed in duplicate (c) and triplicate (d). e, f Whole-cell lysates
from (c) and (d) were analysed by immunoblotting for antiviral signaling with Vinculin (VCL) as loading control. g–i Fibroblasts from SAVI patients were
pre-treated with increasing doses of L-sulforaphane (SFN) (10 and 20 μM) for 72 h before getting challenged with cGAMP (4 µg/mL). Whole-cell lysates
were analysed for late antiviral signaling events by immunoblotting after 24 h of stimulation. Data are from three individual patients. j Supernatants from
(g–i) were collected after 24 h of cGAMP treatment and analysed for type I IFN production. Data are from three individual patients and bars indicated
mean and SEM. k–m Immortalized ﬁbroblasts from SAVI patients were pre-treated with 4-OI (200 μM) for 48 h before treating with cGAMP. After 24 h of
stimulation cells were collected for western blotting (k–m), and type I IFN analysis by bioassay (n). Data display results from three individual SAVI patients
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Primary ﬁbroblast cell lines derived from SAVI patients’ superﬁcial skin
biopsies. Patients with genetically conﬁrmed SAVI were enrolled into the protocol
(ClinicalTrials.gov NCT02974595) at the National Institutes of Health between
2008 and 2015. The protocol was approved by the National Institute of Allergy and
Infectious Diseases (NIAID) IRB at the NIH. Written informed consent was
obtained from all participating patients or their legal guardians (RGM). Superﬁcial
research biopsies were obtained and primary ﬁbroblast cell lines were generated.
Primary cells and culture conditions. Peripheral blood mononuclear cells
(PBMCs) were isolated from healthy donors (blood donors gave written consent as
accordingly to the ethical guidelines at Aarhus University Hospital) by Ficoll Paque
gradient centrifugation (GE Healthcare). Monocytes were separated using a
monocyte enrichment kit (STEMCELL) according to the manufacturer’s instruc-
tions or from PBMCs by adherence to plastic in RPMI 1640 supplemented with
10% AB-positive human serum. Differentiation of monocytes to macrophages was
achieved by culturing in Dulbecco’s Modiﬁed Eagle Medium (DMEM) supple-
mented with 10% heat inactivated AB-positive human serum 9 days in the presence
of 10 ng/ml M-CSF (R&D Systems). Bone marrow cells were obtained from Nrf2
knockout animals purchased from the Jackson laboratory and were subsequently
differentiated in macrophages using the following protocol. The cells were differ-
entiated over 6 days using 20–40% L929 supernatant (M-CSF producing murine
ﬁbroblast cell line) in RPMI (Lonza) supplemented with 10% heat-inactivated
FCS (Sigma-Aldrich), 100 Uml−1 penicillin, 100 μg ml−1 streptomycin, and
292 µgml−1 L-glutamine (Gibco).
Drugs, cytokine, and plasmids. L-sulforaphane (SFN) was purchased from San-
tacruz Bio and dissolved in DMSO (Sigma-Aldrich). N-acetyl-L-cysteine (L-NAC)
was purchased from Santacruz Bio and dissolved in water. pH of the L-NAC
solution was adjusted to 7. ML385 was purchased from Axon MedChem and
dissolved in DMSO. Interferon-α (A2) was obtained from PBL Assay Science. 4-
octyl-itaconate (4-OI) was chemically synthetized by Thomas B. Poulsen (Aarhus
University, Denmark) and was dissolved in DMSO (see dedicated section for
chemical synthesis). TLR agonists including gardiquimod, LPS, CpG DNA, and
Poly (I:C) were all obtained from Invivogen and resuspended in water as per
manufacturer’s recommendations. Construction of the human Nrf2 overexpression
plasmid is described here48.
Short-interfering RNA (siRNA)-mediated knockdown. For short interfering
RNA experiments, A549 or HaCat cells were transfected in six-well plates with 80
pmol of human Nrf2(1) (sc-37030), Nrf2(2) (sc-44332), Keap1 (sc-43878), STING
(sc-92042), HO-1 (sc-35554), Atg7 (sc-41447), ULK1 (sc-44182), p62/SQSTM1
(sc-29679), IFN α/β R α chain (sc-35637), IFN α/β R β chain (sc-40091) or control
si RNA (sc-37007) diluted in serum and antibiotic free DMEM and using Lipo-
fectamine RNAi Max as per manufacturer’s instructions. A549 were incubated for
48 h and HaCat cells 72 h in the presence of the siRNA before being processed.
For the Nrf2-gene RNAi screening experiment, A549 cells were transfected in
six-well plates with 80 pmol of a cherry-pick RNAi library from Dharmacon.
siRNA sequences were diluted in serum and antibiotic free DMEM and transfected
using Lipofectamine RNAi Max as per manufacturer’s instructions. Cells were
incubated for 48 h before being assessed for STING expression by immunoblotting.
For gene interference in primary human monocyte-derived macrophages
(hMDMs), cells were transfected on day 6 and 8 post isolation in 48-well plates
with a pool of Nrf2 speciﬁc siRNAs (sc-37030), or siRNA controls (30 nM) using
Lipofectamine RNAiMax (Life technologies) according to the manufacturer’s
instructions, followed by stimulation on day 10.
Transduction of A549 cells and RAW 264.7 murine macrophages with len-
tiviral CRISPR/Cas9. A549 and RAW 264.7 cells deﬁcient in Nrf2/Keap1 were
generated using CRISPR/Cas9 system, more speciﬁcally by employing the pLen-
tiCRISPR/Cas9 V2 vector (Addgene) and guide RNA (gRNA) sequences consisting
of gene-speciﬁc CRISPR RNA – hNRF2 (T3 5′-GCTGAAAACTTCGAGATATA-
3′), hKEAP1 (T1 5′-GGGCGGGCTGTTGTACGCCG-3′, T2 5′-CTGGAGTCGG
TGTTGCCGTC-3′) mNrf2 (T1 5′-GACTTGGAGTTGCCACCGCC-3′), mKeap1
(T2 5′-GGCATACATCACTGCGTCCC-3′). For controls, the pLentiCRISPR/Cas9
V2 vector was used without a gRNA sequence. Guides were cloned into the vector
and infectious lenti-virions were produced by transfecting HEK293T cells with
pLentiCRISPR/Cas9 V2 vector, pMD.2G (Addgene), pRSV.Rev (Addgene) and
pMDlg/p-RRE (Addgene). Knockout of the targeted gene-products were validated
by immunoblotting or other functional assays.
Genomic deletion of Nrf2 peak region in A549 cells. To achieve maximum
knockout efﬁciency for the dual cutting for knockout, we designed two-speciﬁc
gRNAs on each site of region of interest (NRF2-L-T1: 5′-GCCGGTGACTTCA
TCCGGCC-3′; NRF2-L-T2: 5′-AGAGCAGCGCCCTCTAGCGG-3′; NRF2-R-T1:
5′-AACCAGACGCCATGCCCGTC-3′; NRF2-R-T2: 5′-CTACCCTCTCTCAGA
CCAAC-3′). NRF2-R-T1: 5′-AACCAGACGCCATGCCCGTC-3′; NRF2-R-T2:
5′-CTACCCTCTCTCAGACCAAC-3′). To generate the gRNA expression vectors,
complementary gRNA oligos were annealed in 1X NEB buffer 2, cloned into the
lentiGuide-Puro plasmid (a gift from Feng Zhang, Addgene plasmid #52963), and
subsequently validated by Sanger sequencing. To generate the gRNA expression
vectors, complementary gRNA oligos were annealed in 1X NEB buffer 2, cloned
into the lentiCRISPRv2 plasmid (a gift from Feng Zhang, Addgene plasmid
#52961), and subsequently validated by Sanger sequencing.
dsDNA and cGAMP stimulation of cells. HSV-60 naked, a viral dsDNA motif
and 2′3′-cGAMP, a STING ligand, were both obtained from Invivogen. Intracel-
lular delivery of dsDNA and cGAMP was achieved using Lipofectamine 2000
(Invitrogen) diluted in serum-free medium with a ratio of Lipo.dsDNA/cGAMP of
1:1. Final concentration for both dsDNA and cGAMP was 4 μg mL−1.
HSV production, quantiﬁcation, and infection. HSV-1 KOS strain expressing
GFP (HSV-1–GFP), HSV-2 333 strain and HSV-2 MS strain were kindly provided
by Søren Paludan (Aarhus University, Aarhus, Denmark). All HSVs were propa-
gated in Vero cells, puriﬁed by ultra-centrifugation, and titrated by plaque assay.
A549 and HaCat cells were infected with the different HSVs at a multiplicity of
infection (MOI) of 0.01 in a small volume of serum-free medium for 1 h at 37 °C.
Prior to analysis, cells were incubated with DMEM complete for an additional day
of culture.
Western blot. Four hundred thousand THP1 cells and 1 million A549 or HaCat
cells were lysed in 100 μL or 60 μL of ice-cold Pierce RIPA lysis buffer (Thermo
Scientiﬁc) supplemented with 10 mM NaF, 1X complete protease cocktail inhibitor
(Roche) and 5 IUmL−1 benzonaze (Sigma), respectively. Protein concentration
was determined using a BCA protein assay kit (Thermo Scientiﬁc). Whole-cell
lysates were denatured for 3 min at 95 °C in presence of 1X XT Sample Buffer
(BioRad) and 1X XT reducing agent (BioRad). A total of 10–40 μg of reduced
samples was separated by SDS-PAGE on 4–20% Criterion TGX precast gradient
gels (BioRad). Each gel was run initially for 15 min at 70 V and 45 min at 120 V.
Transfer onto PVDF membranes (BioRad) was done using a Trans-Blot Turbo
Transfer system for 7 min. Membranes were blocked for 1 h with 5% skim-milk
(Sigma-Aldrich) at room temperature in PBS supplemented with 0.05% Tween-20
(PBST). Membranes were fractionated in smaller pieces and probed overnight at
4 °C with any of the following speciﬁc primary antibodies in PBST: anti-Nrf2
(12721, Cell Signaling 1:1000), anti-MDA5 (5321, Cell Signaling 1:1000), anti-
MAVS (3993, Cell Signaling 1:1000), anti-TBK1/NAK (3013, Cell Signaling
1:1000), anti-phospho-TBK1/NAK (5483, Cell Signaling 1:1000), anti-MyD88
(4283, Cell Signaling 1:1000), anti-NF-kB p65 (8242, Cell Signaling 1:1000), anti-
Atg7 (8558, Cell Signaling 1:1000), anti-ULK1 (8054, Cell Signaling 1:1000), anti-
SQSTM1/p62 (8025, Cell Signaling 1:1000), anti-RIG-I (3743, Cell Signaling
1:1000), anti-IRF3 (11904, Cell Signaling 1:1000), anti-phospho-IRF3 (4947, Cell
Signaling 1:500), anti-STAT1 (9172, Cell Signaling 1:1000), anti-phospho-STAT1
(7649, Cell Signaling 1:1000), anti-HO-1 (5853, Cell Signaling 1:1000), anti-IFIT1
(14769, Cell Signaling 1:1000), anti-Nrf2 (12721, Cell Signaling 1:1000), anti-cGAS
(15102, Cell Signaling 1:1000), anti-ISG15 (2758, Cell Signaling 1:1000), anti-
STING (13647, Cell Signaling 1:1000), anti-IFI16 (sc-8023, Santacruz Bio 1:1000),
anti-NqO1 (3187, Cell Signaling 1:1000), anti-MDM2 (86934, Cell Signaling
1:1000), anti-Cyclin B1 (12231, Cell Signaling 1:1000), anti-HSV-1–2 VP5 (ab6508,
AbCam 1:1000) and anti-Vinculin (18799, Cell Signaling 1:1000) used as loading
control. After three washes in PBST, secondary antibodies, peroxidase-conjugated
F(ab)2 donkey anti-mouse IgG (H+L) (1:10000) or peroxidase-conjugated F(ab)2
donkey anti-rabbit IgG (H+L) (1:10000) (Jackson Immuno Research) were added
to the membrane in PBST 1% milk for 1 h at room temperature. All membranes
were washed three times and exposed using either the SuperSignal West Pico PLUS
chemiluminescent substrate or the SuperSignal West Femto maximum sensitivity
substrate (Thermo Scientiﬁc) and an Image Quant LAS4000 mini imager (GE
Healthcare). The levels of proteins were quantiﬁed by densitometry using the
Image J software.
Uncropped images of the western blots are provided in Supplementary
ﬁgure 15.
Semi-native WB dimerization assay. IRF3, phosphor-IRF3 and STING dimer-
ization was assayed under semi-native conditions. Cells were lysed in ice-cold
Pierce RIPA lysis buffer (Thermo Scientiﬁc) supplemented with 10 mM NaF, 1X
complete protease cocktail inhibitor (Roche) and 5 IUmL−1 benzonaze (Sigma).
Protein concentration was determined using a BCA protein assay kit (Thermo
Scientiﬁc). Whole-cell lysates were mixed with 1X XT Sample Buffer (BioRad);
samples were neither reduced nor heated before separation was done on 4–20%
Criterion TGX precast gradient gels (BioRad) by SDS-PAGE electrophoresis. Each
gel was run initially for 15 min at 70 V and 15 min at 120 V. Transfer onto PVDF
membranes (BioRad) was done using a Trans-Blot Turbo Transfer system for 7
min. Membranes were blocked for 1 h with 5% skim-milk (Sigma-Aldrich) at room
temperature in PBS supplemented with 0.05% Tween-20 (PBST). Membranes were
probed overnight at 4 °C with any of the following speciﬁc primary antibodies in
PBST: anti-IRF3 (11904, Cell Signaling 1:1000), anti-phospho-IRF3 (4947, Cell
Signaling 1:500), and anti-STING (13647, Cell Signaling 1:1000). After three
washes in PBST, secondary antibodies, peroxidase-conjugated F(ab)2 donkey anti-
rabbit IgG (H+L) (1:10,000) (Jackson Immuno Research) were added to the
membrane in PBST 1% milk for 1 h at room temperature. All membranes were
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washed three times and exposed using either the SuperSignal West Pico PLUS
chemiluminescent substrate or the SuperSignal West Femto maximum sensitivity
substrate (Thermo Scientiﬁc).
qPCR analysis. Gene expression was determined by real-time quantitative PCR,
using TaqMan detection systems (Applied Biosciences). RNA was extracted using
the High Pure RNA Isolation kit (Roche) and RNA quality was assessed by
Nanodrop spectrometry (Thermo Fisher). RNA levels for human Ifnb1
(Hs01077958_s1), Cxcl10 (Hs00171051_m1), Tmem173 (Hs00736955_g1), Hmox-
1 (Hs01110250_m1), Nfe2l2 (Nrf2) (Hs00975961_g1), Mb21d1 (cGas)
(Hs00403553_m1) and β-Actin (Hs01060665_g1) were analysed using premade
TaqMan assays and the RNA-to-Ct-1-Step kit according to the manufacturer’s
recommendations (Applied Biosciences).
RNAseq and ChIP-seq analysis. One million of A549 cells silenced or not for
Nrf2 using siRNA were snap-frozen on dry ice. RNA extraction, library prepara-
tion, RNAseq and bioinformatics analysis was performed at Active Motif (Carls-
bad, California, USA). Brieﬂy, the sequencing reads were aligned to human genome
(version Hg19)49 and the resulting binary alignment (BAM) ﬁles were used to
calculate the gene counts that represent total number of sequencing reads aligned
to a gene. To identify differentially expressed genes between control and Nrf2
siRNA-treated samples, DESeq2 algorithm was used50. The list of differentially
expressed genes from DESeq2 output were selected based on 10% adjusted P-value
level and a FDR of 0.1. Among these, the highly signiﬁcant genes (FDR <10%)
genes were selected that are involved in pattern recognition signaling, antiviral
signaling and experimentally identiﬁed Nrf2 transcriptional targets51–53. To depict
these genes as heatmap, count data were transformed using regularized-logarithm
transformation (rld)50 and the resulting values were mean-centered and plotted
usinged pheatmap package available in bioconductor repository (Raivo Kolde
(2015). pheatmap: Pretty Heatmaps. R package version1.0.8. http://CRAN.R-
project.org/package=pheatmap). Gene ontology and KEGG pathway enrichment
analysis was done using DAVID bioinformatics resources portal54.
Chromatin immunoprecipitation (ChIP). ChIP was performed by Active Motif
(Carlsbad, California, USA). A549 cells were ﬁxed with 1% formaldehyde for 15
min and quenched with 0.125M glycine. Chromatin was isolated by the addition of
lysis buffer, followed by disruption with a Dounce homogenizer. Lysates were
sonicated and the DNA sheared to an average length of 300–500 bp. Genomic
DNA (Input) was prepared by treating aliquots of chromatin with RNase, pro-
teinase K and heat for de-crosslinking, followed by ethanol precipitation. Pellets
were resuspended and the resulting DNA was quantiﬁed on a NanoDrop spec-
trophotometer. Extrapolation to the original chromatin volume allowed quantita-
tion of the total chromatin yield.
An aliquot of chromatin (30 µg) was precleared with protein A (for Nrf2) or G
(for Pol2) agarose beads (Invitrogen). Genomic DNA regions of interest were
isolated using 4 µg of target speciﬁc antibody. Complexes were washed, eluted from
the beads with SDS buffer, and subjected to RNase and proteinase K treatment.
Crosslinks were reversed by incubation overnight at 65 °C, and ChIP DNA was
puriﬁed by phenol-chloroform extraction and ethanol precipitation.
Quantitative PCR (QPCR) reactions were carried out in triplicate on speciﬁc
genomic regions using SYBR Green Supermix (BioRad). The resulting signals were
normalized for primer efﬁciency by carrying out QPCR for each primer pair using
Input DNA.
ChIP sequencing (Illumina). ChIP sequencing was performed by Active Motif
(Carlsbad, California, USA). Illumina sequencing libraries were prepared from the
ChIP and Input DNAs by the standard consecutive enzymatic steps of end-pol-
ishing, dA-addition, and adaptor ligation. After a ﬁnal PCR ampliﬁcation step, the
resulting DNA libraries were quantiﬁed and sequenced on Illumina’s NextSeq 500
(75 nt reads, single end). Reads were aligned to the human genome (hg19) using
the BWA algorithm (default settings). Duplicate reads were removed and only
uniquely mapped reads (mapping quality >=25) were used for further analysis.
Alignments were extended in silico at their 3′-ends to a length of 200 bp, which is
the average genomic fragment length in the size-selected library, and assigned to
32-nt bins along the genome. The resulting histograms (genomic “signal maps”)
were stored in bigWig ﬁles. For Nrf2, peak locations were determined using the
MACS algorithm (v2.1.0) with a cutoff of p-value= 1e−7. RNA Pol2-enriched
regions were identiﬁed using the SICER algorithm at a cutoff of FDR 1E-10 and a
max gap parameter of 600 bp. Peaks that were on the ENCODE blacklist of known
false ChIP-Seq peaks were removed. Signal maps and peak locations were used as
input data to Active Motifs proprietary analysis program, which creates Excel
tables containing detailed information on sample comparison, peak metrics, peak
locations and gene annotations.
Measurement of itaconic acid. All the solvents used for extraction and mobile
phase were LC–MS Optima Grade (Fisher Chemical Ltd., Pittsburgh, PA, USA).
The quantiﬁcation of itaconic acid in cell cultures was determined using standard
dilutions of itaconic acid. The stock solution of itaconic acid (Sigma-Aldrich
I29204, St. Louis, MO, USA) was prepared in water with 0.1% formic acid at the
concentration of 1000 µmol/mL. The calibration curve was prepared by serial
diluting 50 µmol/mL to 3.125 µmol/mL in water with 0.1% formic acid resulting in
a linear equation using for quantiﬁcation. Cell culture samples (200 µL supernatant
or 100 µL of pellet) were diluted in 800 µL of methanol. After being vortexed, the
diluted samples were centrifuged at 16,000×g for 5 min at 4 °C and supernatant
were transferred to a new vial and evaporated in a vacuum concentration system
(Savant Instruments, Holbrook, NY, USA) and re-dissolved in 100 µL of water
0.1% formic acid. Itaconic acid was analyzed using an Agilent-1290 ultra-perfor-
mance liquid-chromatography system equipped with autosampler and coupled
with an Agilent-6495 triple-quadrupole mass spectrometry (Agilent Technologies,
Palo Alto, CA, USA). The injection volume of extraction was 5 µL and the auto-
sampler temperature was 4 °C. The separation was performed using an Zorbax
Eclipse column C18 (2.1 × 50 mm × 1.8 µm; Agilent Technologies) at 0.5 mLmin
and 40 °C. The mobile phase A was 0.1% formic acid in water and mobile phase B
0.1% formic acid in acetonitrile. The gradient of mobile phase A starting at 75%,
maintained for 0.2 min, followed by 50% at min 2 to reach the initial state at min
2.2 followed by 0.8 min of re-equilibration. The mass spectrometry was performed
in negative ionization mode. The capillary voltage and nebulizer were set at 1500 V
and 11 V, respectively. The electro-spray ionization source was operated at 290 °C
with ultrahigh-purity nitrogen as cone gas (11 L/min). The desolvation temperature
was 400 °C and the gas ﬂow set at 12 L/min. Nitrogen was used as collosion gas,
and the collosion energy was set at 5 eV for itaconic acid. Multiple reactions
monitoring (MRM) was applied to detect the analyte by the following ion transi-
tions (m/z): Itaconic acid (129.09), 89.1.
The data acquisition, process, and quantiﬁcation were performed using
MassHunter software (Agilent Technologies).
ROS production. Total ROS accumulation was evaluated by ﬂow cytometry using
the H2DCFDA redox sensitive probe. Following siRNA treatment and/or treat-
ment with the appropriate controls, cells were washed in PBS before incubation
with the probe (1 μM) for 30 min at 37 °C. After incubation, cells were washed
twice in PBS before FACS analysis using a Novo Cyte ﬂow cytometer. FlowJo
software was used to analyze the data.
Type I IFN assay. Functional type I IFN was quantiﬁed using the reporter cell line
HEK-Blue IFN-α/β according to the manufacturer’s instructions (Invivogen).
Luciferase assay. For ARE-Luciferase assays, experiments were performed using
the calcium phosphate transfection method. For Are luciferase assays,
HEK293T cells were transfected with 50 ng of pRLTK reporter plasmid, 100 ng of
pP-ARE-Luc reporter, and increasing doses of the expression plasmid encoding for
Nrf2 or STING, along with the appropriate amount of empty vector. After 24 h of
transfection and stimulation, luciferase activity was measured with a dual-luciferase
reporter assay and a GloMax 20/20 luminometer.
Co-immunoprecipitation. HEK293T cells were collected after transfection with the
different overexpression plasmids and resuspended in 300 μl Pierce IP lysis buffer
(Thermo Scientiﬁc) supplemented with 1X Complete Ultra (Roche) and NaF
0.5 mM. Cells were allowed to lyse at 4 °C for 90 min under rotation and cytosolic
supernatants were cleared by centrifugation at 3000×g for 10 min. A volume of 200
μl of cleared lysates were then incubated at 4 °C overnight with an antibody against
STING (Cell Signaling 1:50). On the following day, each lysate was incubated with
pre-washed Dynabeads magnetic protein G (Invitrogen) for 2 h at 4 °C. Immu-
noprecipitated complexes were eluted from the beads with a glycine buffer
(200 mM glycine, pH 2.5), and protein expression was evaluated by western
blotting.
Polysome proﬁling and quantitative PCR. Cells seeded in 10 cm plates cells were
the following day transfected with control siRNAs or siRNAs targeting KEAP,
using Lipofectamine RNAi (Life Technologies) transfection agent according to
manufacturer’s directions. A total of 46 h after transfection media were replenished
with fresh DMEM, 10% FBS and cells cultured for an additional 2 h. Cells were
then treated with 100 μg/mL cycloheximide for 3 min followed by two washes in
ice-cold PBS containing 100 μg/mL cycloheximide. Cells were subsequently
lysed directly in the cell culture plate in 1000 μL of 1X polysome extraction buffer
(1× PEB; 50 mM Tris-HCl at pH 7.4, 150 mM NaCl, 7.5 mM MgCl2, 0.5% Triton
X-100, 500 μg/mL Heparin, 100 μg/mL cycloheximide), scraped off, and incubated
for 5 min on ice. Lysates were cleared by centrifugation at 15,300×g, 4 °C for
10 min. Complexes were separated in 10 mL of linear 1X PEB/10–50% sucrose
gradients by ultra-centrifugation at 150,000×g (35,000 rpm) in a Beckman SW41
rotor for 2.5 h at 4 °C. Twelve 1-mL fractions were collected using a Teledyne/ISCO
fractionation system. Five-hundred microliters from each fraction was vortexed for
20 s after addition of 750 μL of 8M guanidine-HCl and 750 μL of isopropanol and
precipitated overnight at −20 °C. Precipitates were isolated by centrifugation at
17,900×g for 30 min at 4 °C, and pellets were subsequently dissolved in Trizol
solution (Invitrogen). RNA was isolated according to the manufacturer’s protocol
except for one additional 300 µl chloroform extraction prior to isopropanol pre-
cipitation. Pellets were dissolved in 20 µl nuclease-free water (Ambion) and equal
volumes from the fractions were used for quantitative PCR. First-strand cDNA
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synthesis was carried out using equal volumes of RNA and the Maxima First Strand
cDNA Synthesis Kit for qPCR (Thermo Fisher Scientiﬁc) according to manu-
facturer’s protocol. STING mRNA expression levels were measured using the
Maxima Probe qPCR Master Mix (Thermo Fisher Scientiﬁc) and TaqMan primers
and probes (Hs00736955_g1, Thermo Fisher Scientiﬁc) according to manu-
facturer’s protocol. GAPDH mRNA expression levels were measured using Plati-
num SYBR Green qPCR Supermix-UDG (Invitrogen) according to manufacturer’s
protocol and gene-speciﬁc primers (GAPDH (s): 5′-GTCAGCCGCATCTTCTT
TTG-3′, GAPDH (as): 5′-GCGCCCAATACGACCAAATC-3′). An AriaMx Real-
time PCR System (Agilent Technologies, CA, California, United States) were used
for quantiﬁcation of mRNA levels and the X0 method was used for calculations of
relative mRNA levels55.
Synthesis of 4-octyl-itaconate (4-OI). See supplementary methods.
Statistical analysis. Values were expressed as the mean ± SEM. Graphs and sta-
tistics were computed using Graph Pad Prism 7. An unpaired, two-tailed Student’s
t-test was used to determine signiﬁcance of the difference between the control and
each experimental condition. P-values of <0.05 were considered statistically sig-
niﬁcant, ***p < 0.001; **p < 0.01, and *p < 0.05. GSE113522 is the reference Series
for both ChIP-seq and RNA seq: [https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?
acc=GSE113522] SubSeries that are linked to GSE113522: [https://www.ncbi.nlm.
nih.gov/geo/query/acc.cgi?acc=GSE113497] [https://www.ncbi.nlm.nih.gov/geo/
query/acc.cgi?acc=GSE113519]
Data availability
Sequencing data are uploaded to GEO.
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